Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance

MYRIAD GENETICS INC

2025-Q2 EPS reported -$3.59 revenue$409,000,000

GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.
Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.
New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.
GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.